File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Functional materials from the covalent modification of reduced graphene oxide and β-cyclodextrin as a drug delivery carrier

TitleFunctional materials from the covalent modification of reduced graphene oxide and β-cyclodextrin as a drug delivery carrier
Authors
Issue Date2014
Citation
New Journal of Chemistry, 2014, v. 38, n. 1, p. 140-145 How to Cite?
AbstractWe report a drug delivery system based on the covalently reduced graphene oxide (rGO) with p-aminobenzoic acid (rGO-C6H4-COOH) for the loading and targeted delivery of the anticancer drug, doxorubicin (DOX). The colloidal solution of rGO-C6H4-COOH conjugated by polyethyleneimine (PEI) and Biotin was prepared. This endows the colloidal solution of rGO-C6H4-CO-NH-PEI-NH-CO-Biotin, which presents excellent water-solubility and targeting as a drug delivery system. β-Cyclodextrin (β-CD) molecules, which are host molecules for accommodating guest molecules, such as water insoluble anticancer drugs, were introduced to reduce the cytotoxicity of the drug delivery system and to improve the biocompatibility. The drug delivery of rGO-C6H 4-CO-NH-PEI-NH-CO-CD-Biotin has a ∼24.64% drug (DOX) loading ratio. The drug release behavior was pH dependent at higher DOX concentrations, but salt dependent at lower DOX concentrations, which could be exploited for controlled drug release in cancer cells. The DOX loaded on rGO-C 6H4-CO-NH-PEI-NH-CO-CD-Biotin could effectively induce HepG2 cancer cell apoptosis. This can be explained by the conjugation of DOX and rGO-C6H4-CO-NH-PEI-NH-CO-CD-Biotin being able to arrest the cancer cells in the G2 phase, which is the most sensitive to the anticancer drug. © The Royal Society of Chemistry and the Centre National de la Recherche Scientifique 2014.
Persistent Identifierhttp://hdl.handle.net/10722/349019
ISSN
2023 Impact Factor: 2.7
2023 SCImago Journal Rankings: 0.521

 

DC FieldValueLanguage
dc.contributor.authorWei, Guangcheng-
dc.contributor.authorDong, Renhao-
dc.contributor.authorWang, Dong-
dc.contributor.authorFeng, Lei-
dc.contributor.authorDong, Shuli-
dc.contributor.authorSong, Aixin-
dc.contributor.authorHao, Jingcheng-
dc.date.accessioned2024-10-17T06:55:43Z-
dc.date.available2024-10-17T06:55:43Z-
dc.date.issued2014-
dc.identifier.citationNew Journal of Chemistry, 2014, v. 38, n. 1, p. 140-145-
dc.identifier.issn1144-0546-
dc.identifier.urihttp://hdl.handle.net/10722/349019-
dc.description.abstractWe report a drug delivery system based on the covalently reduced graphene oxide (rGO) with p-aminobenzoic acid (rGO-C6H4-COOH) for the loading and targeted delivery of the anticancer drug, doxorubicin (DOX). The colloidal solution of rGO-C6H4-COOH conjugated by polyethyleneimine (PEI) and Biotin was prepared. This endows the colloidal solution of rGO-C6H4-CO-NH-PEI-NH-CO-Biotin, which presents excellent water-solubility and targeting as a drug delivery system. β-Cyclodextrin (β-CD) molecules, which are host molecules for accommodating guest molecules, such as water insoluble anticancer drugs, were introduced to reduce the cytotoxicity of the drug delivery system and to improve the biocompatibility. The drug delivery of rGO-C6H 4-CO-NH-PEI-NH-CO-CD-Biotin has a ∼24.64% drug (DOX) loading ratio. The drug release behavior was pH dependent at higher DOX concentrations, but salt dependent at lower DOX concentrations, which could be exploited for controlled drug release in cancer cells. The DOX loaded on rGO-C 6H4-CO-NH-PEI-NH-CO-CD-Biotin could effectively induce HepG2 cancer cell apoptosis. This can be explained by the conjugation of DOX and rGO-C6H4-CO-NH-PEI-NH-CO-CD-Biotin being able to arrest the cancer cells in the G2 phase, which is the most sensitive to the anticancer drug. © The Royal Society of Chemistry and the Centre National de la Recherche Scientifique 2014.-
dc.languageeng-
dc.relation.ispartofNew Journal of Chemistry-
dc.titleFunctional materials from the covalent modification of reduced graphene oxide and β-cyclodextrin as a drug delivery carrier-
dc.typeArticle-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1039/c3nj00690e-
dc.identifier.scopuseid_2-s2.0-84890256898-
dc.identifier.volume38-
dc.identifier.issue1-
dc.identifier.spage140-
dc.identifier.epage145-
dc.identifier.eissn1369-9261-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats